Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage

Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and raises the price t

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.57) per share which missed the analyst conse

SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.63 per share which beat the analyst consens

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for

(Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the s

U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, S

SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.42) per share which missed the analyst conse

SCYNEXIS, Inc. (NASDAQ: SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company focused on developing innovative new therapies

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1123525

SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.25 per share which beat the analyst consens

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome a

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome an

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome a

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome an

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the deve

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.17) per share which beat the analyst consens

Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and lowers the price t

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Ph

No safety concerns or dose limiting toxicities observedSCY-247 was able to achieve target exposures

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company

  On Friday, 497 companies set new 52-week lows.

  Friday's session saw 75 companies set new 52-week lows.

  On Wednesday, 258 companies hit new 52-week lows.

  Tuesday's session saw 325 companies set new 52-week lows.

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus T

  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings f

Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednes

  On Tuesday, 951 companies hit new 52-week lows.

  Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report

    On Monday, 721 companies achieved new lows for the year.

  On Friday, 431 companies hit new 52-week lows.

Gainers Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading

    On Thursday, 236 companies hit new 52-week lows.